Anti-Polymer Antibody Detection via Polymer-Modified Carrier Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective methods to detect anti-polymer antibodies in individuals receiving or treated with water soluble polymer-modified drugs, as these antibodies can lead to rapid clearance of the drugs and reduced therapeutic effectiveness.
Innovation Solution
The method involves contacting a biological sample with a water soluble polymer-modified carrier, such as a non-linear polyethylene glycol derivative, to detect binding of antibodies, which indicates the presence of anti-polymer antibodies, using techniques like flow-cytometry or ELISA.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If water soluble polymer modification is applied to polypeptide drugs, then drug stability and half-life are improved, but immunogenicity increases due to anti-polymer antibody formation
Solution Approach 1:
The patent modifies the polymer structure parameters by using non-linear PEG derivatives with specific molecular weights and architectures (e.g., branched or star-shaped structures) to reduce immunogenicity while maintaining extended half-life benefits. This changes the physical-chemical parameters of the polymer to achieve better biocompatibility
Solution Approach 2:
The patent creates composite structures by conjugating polypeptide drugs with water-soluble polymer modifications, forming hybrid molecules that combine the therapeutic properties of the polypeptide with the stability and solubility benefits of the polymer, while carefully selecting polymer characteristics to minimize immune response
2Measurement precision
If conventional detection methods are used for anti-polymer antibodies, then detection capability is limited, but pre-screening and monitoring effectiveness are reduced
Solution Approach 1:
The patent enables pre-screening of patients for pre-existing anti-polymer antibodies before initiating therapy with polymer-modified drugs. This preliminary detection allows clinicians to identify patients at risk for rapid drug clearance and select alternative treatments, improving overall therapeutic reliability
Solution Approach 2:
The patent implements monitoring capabilities that provide feedback on antibody development during therapy. By detecting anti-polymer antibodies at various time points, clinicians can adjust dosing strategies or switch to non-polymer-modified drugs when antibody levels indicate potential treatment failure
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for pre-screening and monitoring of individuals for anti-polymer antibodies, enabling tailored dosing strategies and identifying those who may require non-polymer-modified drugs, thereby improving the efficacy and safety of polymer-modified drug treatments.
Implementation Method 1
contacting a sample from the individual with a water soluble polymer-modified carrier and detecting binding of antibody to the water soluble polymer on the water soluble polymer-modified carrier
Data Source
AI summary
The present invention provides analytical methods for detecting anti-polymer antibody in an individual. The methods involve contacting a sample from the individual with a water soluble polymer-modified carrier and detecting binding of antibody to the water soluble polymer on the water soluble polymer-modified carrier wherein binding is indicative of the presence of antibody to the water polymer-modified polypeptide. Antibody may be detected to water soluble polymers such as polyethylene glycol, polysialic acid, dextran, hydroxyalkyl starch, or hydroxyethyl starch. When antibody to the water soluble polymer polyethylene glycol is to be detected, the carrier is modified with a non-linear polyethylene glycol derivative.